Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Citius Oncology is a clinical-stage biopharmaceutical company focused on developing novel oncology therapeutics, with its lead asset LYMPHIR (denileukin diftitox) targeting cutaneous T-cell lymphoma (CTCL) and peripheral T-cell lymphoma (PTCL). The company operates as a pre-revenue entity burning cash to advance clinical trials, with stock performance driven by regulatory milestones, clinical data readouts, and capital raising events. With a current ratio of 0.83 and negative operating cash flow, the company faces near-term liquidity pressures typical of late-stage clinical development.
Citius Oncology operates a binary risk/reward model typical of clinical-stage biotechs: invest capital in clinical trials and regulatory submissions, then monetize through product commercialization or asset sale/licensing. LYMPHIR represents a reformulated version of denileukin diftitox targeting rare hematologic malignancies with limited treatment options, potentially commanding premium pricing ($150K-200K+ annual treatment cost estimate) due to orphan drug status and unmet medical need. The company's value creation depends entirely on successful FDA approval and market penetration, with no diversified revenue base to cushion development setbacks.
FDA regulatory decisions and milestone achievements for LYMPHIR (BLA acceptance, approval timing, label scope)
Clinical trial data readouts showing efficacy, safety, and differentiation versus existing CTCL/PTCL therapies
Capital raising events (equity offerings, debt financing) that dilute existing shareholders but extend cash runway
Partnership or licensing announcements that validate technology and provide non-dilutive funding
Competitive developments in CTCL/PTCL treatment landscape affecting market opportunity perception
Binary FDA approval risk - single-asset company faces total value destruction if LYMPHIR fails to gain approval or receives restricted label
Rare disease market size limitations - even with approval, CTCL/PTCL represent small patient populations (~3,000-5,000 addressable patients) limiting peak revenue potential versus development costs
Reimbursement uncertainty - payers increasingly scrutinizing high-cost oncology drugs, particularly for rare indications, creating pricing pressure and market access barriers
Established CTCL therapies (Adcetris, Poteligeo, Valchlor) and emerging CAR-T approaches may limit LYMPHIR market share even if approved
Larger pharmaceutical companies with superior commercial infrastructure and sales forces could out-execute in rare disease markets
Patent expiration risk and biosimilar competition if LYMPHIR achieves commercial success, though timeline extends beyond 2030
Critical liquidity constraint - 0.83 current ratio and negative $15-20M annual cash burn suggests runway of 12-18 months maximum, forcing near-term dilutive financing
Equity dilution risk - with $100M market cap and ongoing capital needs, future raises could significantly dilute existing shareholders (30-50%+ dilution likely)
No debt capacity - minimal existing debt but also limited ability to raise non-dilutive debt financing given pre-revenue status and lack of tangible assets
low - Clinical-stage biotech valuations are driven primarily by binary clinical/regulatory outcomes rather than GDP or economic cycles. However, severe recessions can impact: (1) ability to raise capital as risk appetite declines, (2) healthcare spending priorities, and (3) acquisition appetite from larger pharma partners. The company's development timeline and FDA interactions are largely insulated from near-term economic fluctuations.
Rising interest rates negatively impact Citius through two mechanisms: (1) Higher discount rates compress the present value of distant future cash flows (potential product revenues 2-5+ years out), making speculative biotech investments less attractive relative to risk-free alternatives. (2) Tighter financial conditions reduce access to growth capital and increase dilution risk when raising funds. With negative cash flow and low current ratio, the company is vulnerable to deteriorating financing conditions. The 10-year Treasury yield serves as the risk-free benchmark against which speculative biotech equity returns are evaluated.
Moderate - While the company has minimal debt (0.07 debt/equity), credit market conditions significantly affect its ability to raise capital. Widening high-yield spreads signal risk-off sentiment that makes equity financing for pre-revenue biotechs more difficult and dilutive. Tight credit conditions can also reduce M&A activity from larger pharmaceutical acquirers who rely on debt financing for deals, limiting potential exit opportunities.
growth - Highly speculative, binary-outcome investors seeking asymmetric returns from clinical/regulatory catalysts. Typical holders include biotech-focused hedge funds, venture capital crossover funds, and retail investors with high risk tolerance. The -45.7% six-month return and -8.9% three-month return reflect typical pre-approval volatility. Not suitable for value or income investors given negative earnings, no dividends, and balance sheet constraints. Momentum traders may engage around specific catalyst dates (FDA decisions, data readouts).
high - Clinical-stage single-asset biotechs exhibit extreme volatility with 50-80%+ intraday moves common around binary events. The stock's -45.7% six-month decline followed by partial recovery demonstrates characteristic whipsaw behavior. Implied volatility typically exceeds 80-100% around regulatory decision dates. Beta likely exceeds 2.0 relative to broader biotech indices, with correlation to sector sentiment rather than fundamental business drivers.